Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 119

1.

Activity of Cefepime-Zidebactam against Multidrug-Resistant (MDR) Gram-Negative Pathogens.

Thomson KS, AbdelGhani S, Snyder JW, Thomson GK.

Antibiotics (Basel). 2019 Mar 23;8(1). pii: E32. doi: 10.3390/antibiotics8010032.

2.

An Improved Extended-Spectrum-β-Lactamase Detection Test Utilizing Aztreonam plus Clavulanate.

Thomson GK, Ayaz M, Lutes K, Thomson KS.

J Clin Microbiol. 2017 Dec 26;56(1). pii: e01309-17. doi: 10.1128/JCM.01309-17. Print 2018 Jan.

3.

Translation of Cardiac Myosin Activation with 2-deoxy-ATP to Treat Heart Failure via an Experimental Ribonucleotide Reductase-Based Gene Therapy.

Thomson KS, Odom GL, Murry CE, Mahairas GG, Moussavi-Harami F, Teichman SL, Chen X, Hauschka SD, Chamberlain JS, Regnier M.

JACC Basic Transl Sci. 2016 Dec;1(7):666-679. doi: 10.1016/j.jacbts.2016.07.006.

4.

The Immaculate Carbapenemase Study.

Thomson KS.

J Clin Microbiol. 2017 Jun;55(6):1608-1611. doi: 10.1128/JCM.00430-17. Epub 2017 Apr 12.

5.

A Novel Topical Combination Ointment with Antimicrobial Activity against Methicillin-Resistant Streptococcus aureus, Gram-Negative Superbugs, Yeasts, and Dermatophytic Fungi.

Thomson KS, Thomson GK, Biehle J, Deeb A, Crawford J, Herrera R.

Curr Ther Res Clin Exp. 2016 Jul 20;83:8-12. doi: 10.1016/j.curtheres.2016.07.001. eCollection 2016.

6.

Cardiac Myosin Activation with Gene Therapy Produces Sustained Inotropic Effects and May Treat Heart Failure with Reduced Ejection Fraction.

Teichman SL, Thomson KS, Regnier M.

Handb Exp Pharmacol. 2017;243:447-464. doi: 10.1007/164_2016_31. Review.

7.

Coproduction of KPC-18 and VIM-1 Carbapenemases by Enterobacter cloacae: Implications for Newer β-Lactam-β-Lactamase Inhibitor Combinations.

Thomson GK, Snyder JW, McElheny CL, Thomson KS, Doi Y.

J Clin Microbiol. 2016 Mar;54(3):791-4. doi: 10.1128/JCM.02739-15. Epub 2015 Dec 30.

8.

Comparison of the Carba NP, Modified Carba NP, and Updated Rosco Neo-Rapid Carb Kit Tests for Carbapenemase Detection.

AbdelGhani S, Thomson GK, Snyder JW, Thomson KS.

J Clin Microbiol. 2015 Nov;53(11):3539-42. doi: 10.1128/JCM.01631-15. Epub 2015 Aug 26.

9.

Indirect Tris-EDTA Disk Testing Using Imipenem and Meropenem for Detection of OXA-48 Carbapenemase Production.

Thomson GK, AbdelGhani S, Snyder JW, Thomson KS.

J Clin Microbiol. 2015 Nov;53(11):3705-6. doi: 10.1128/JCM.02094-15. Epub 2015 Aug 19. No abstract available.

10.

Identification of Gram-Negative Bacteria and Genetic Resistance Determinants from Positive Blood Culture Broths by Use of the Verigene Gram-Negative Blood Culture Multiplex Microarray-Based Molecular Assay.

Ledeboer NA, Lopansri BK, Dhiman N, Cavagnolo R, Carroll KC, Granato P, Thomson R Jr, Butler-Wu SM, Berger H, Samuel L, Pancholi P, Swyers L, Hansen GT, Tran NK, Polage CR, Thomson KS, Hanson ND, Winegar R, Buchan BW.

J Clin Microbiol. 2015 Aug;53(8):2460-72. doi: 10.1128/JCM.00581-15. Epub 2015 May 20.

11.

Clonality and Resistome analysis of KPC-producing Klebsiella pneumoniae strain isolated in Korea using whole genome sequencing.

Lee Y, Kim BS, Chun J, Yong JH, Lee YS, Yoo JS, Yong D, Hong SG, D'Souza R, Thomson KS, Lee K, Chong Y.

Biomed Res Int. 2014;2014:352862. doi: 10.1155/2014/352862. Epub 2014 Jul 3.

12.

Proangiogenic microtemplated fibrin scaffolds containing aprotinin promote improved wound healing responses.

Thomson KS, Dupras SK, Murry CE, Scatena M, Regnier M.

Angiogenesis. 2014 Jan;17(1):195-205. doi: 10.1007/s10456-013-9388-z. Epub 2013 Oct 15.

13.

Lowering of third generation cephalosporin breakpoints.

Thomson KS.

Clin Infect Dis. 2013 Dec;57(11):1663-4. doi: 10.1093/cid/cit569. Epub 2013 Sep 4. No abstract available.

PMID:
24006448
14.

Activity of tedizolid (TR-700) against well-characterized methicillin-resistant Staphylococcus aureus strains of diverse epidemiological origins.

Thomson KS, Goering RV.

Antimicrob Agents Chemother. 2013 Jun;57(6):2892-5. doi: 10.1128/AAC.00274-13. Epub 2013 Apr 9.

15.

Prevascularized microtemplated fibrin scaffolds for cardiac tissue engineering applications.

Thomson KS, Korte FS, Giachelli CM, Ratner BD, Regnier M, Scatena M.

Tissue Eng Part A. 2013 Apr;19(7-8):967-77. doi: 10.1089/ten.tea.2012.0286. Epub 2013 Jan 14.

16.

Production of KPC-2 alone does not always result in β-lactam MICs representing resistance in gram-negative pathogens.

Roth AL, Thomson KS, Lister PD, Hanson ND.

J Clin Microbiol. 2012 Dec;50(12):4183-4. doi: 10.1128/JCM.02194-12. Epub 2012 Sep 12. No abstract available.

17.

Detection of gram-negative β-lactamase producing pathogens in the clinical lab.

Thomson KS.

Curr Pharm Des. 2013;19(2):250-6. Review.

PMID:
22894616
18.

Double-carbapenem therapy not proven to be more active than carbapenem monotherapy against KPC-positive Klebsiella pneumoniae.

Thomson KS.

Antimicrob Agents Chemother. 2012 Jul;56(7):4037; author reply 4038. doi: 10.1128/AAC.06409-11. No abstract available.

19.

KPC screening by updated BD Phoenix and Vitek 2 automated systems.

Thomson KS, Robledo IE, Vázquez GJ, Moland ES.

J Clin Microbiol. 2011 Sep;49(9):3386-7. doi: 10.1128/JCM.00772-11. Epub 2011 Jul 6.

20.

Extended-spectrum-beta-lactamase, AmpC, and Carbapenemase issues.

Thomson KS.

J Clin Microbiol. 2010 Apr;48(4):1019-25. doi: 10.1128/JCM.00219-10. Epub 2010 Feb 24. Review. No abstract available.

21.

First report of CTX-M-14 producing clinical isolates of Salmonella serovar Typhimurium from Egypt.

AbdelGhani SM, Moland ES, Black JA, Hanson ND, Goering RV, Amine MA, Saafan AE, Gaafar M, Younan M, Thomson KS.

J Infect Dev Ctries. 2009 Dec 14;4(1):58-60. No abstract available.

22.

Positive extended-spectrum-beta-lactamase (ESBL) screening results may be due to AmpC beta-lactamases more often than to ESBLs.

Munier GK, Johnson CL, Snyder JW, Moland ES, Hanson ND, Thomson KS.

J Clin Microbiol. 2010 Feb;48(2):673-4. doi: 10.1128/JCM.01544-09. Epub 2009 Dec 2. No abstract available.

23.

In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii and selection of tigecycline-amikacin synergy.

Moland ES, Craft DW, Hong SG, Kim SY, Hachmeister L, Sayed SD, Thomson KS.

Antimicrob Agents Chemother. 2008 Aug;52(8):2940-2. doi: 10.1128/AAC.01581-07. Epub 2008 Jun 2.

24.

Irreproducible piperacillin/tazobactam minimum inhibitory concentrations in microdilution tests with Escherichia coli strains.

Thomson KS, Black J, Moland ES, Reuben J, Wiles T, Brasso W.

Int J Antimicrob Agents. 2008 Jan;31(1):83-5. Epub 2007 Nov 8. No abstract available.

PMID:
17996426
25.
26.

Convenient test using a combination of chelating agents for detection of metallo-beta-lactamases in the clinical laboratory.

Kim SY, Hong SG, Moland ES, Thomson KS.

J Clin Microbiol. 2007 Sep;45(9):2798-801. Epub 2007 Jun 27.

27.

In vitro studies with DQ-113 and comparison fluoroquinolones to determine propensities to select resistance in gram-positive cocci.

Hong SG, Moland ES, Wickman PA, Black JA, Hossain A, Hanson ND, Thomson KS.

Antimicrob Agents Chemother. 2007 Apr;51(4):1512-4. Epub 2007 Jan 12.

28.

Klebsiella pneumoniae isolate producing at least eight different beta-lactamases, including AmpC and KPC beta-lactamases.

Moland ES, Hong SG, Thomson KS, Larone DH, Hanson ND.

Antimicrob Agents Chemother. 2007 Feb;51(2):800-1. Epub 2006 Dec 4. No abstract available.

29.

In vitro development of resistance to DX-619 and other quinolones in enterococci.

Wickman PA, Black JA, Smith Moland E, Thomson KS, Hanson ND.

J Antimicrob Chemother. 2006 Dec;58(6):1268-73. Epub 2006 Oct 24.

PMID:
17062613
30.

Prevalence of newer beta-lactamases in gram-negative clinical isolates collected in the United States from 2001 to 2002.

Moland ES, Hanson ND, Black JA, Hossain A, Song W, Thomson KS.

J Clin Microbiol. 2006 Sep;44(9):3318-24.

31.

Prophylactic anti-tumor effects in a B cell lymphoma model with DNA vaccines delivered on polyethylenimine (PEI) functionalized PLGA microparticles.

Pai Kasturi S, Qin H, Thomson KS, El-Bereir S, Cha SC, Neelapu S, Kwak LW, Roy K.

J Control Release. 2006 Jul 20;113(3):261-70. Epub 2006 May 3.

PMID:
16793161
32.

First occurrence of a Pseudomonas aeruginosa isolate in the United States producing an IMP metallo-beta-lactamase, IMP-18.

Hanson ND, Hossain A, Buck L, Moland ES, Thomson KS.

Antimicrob Agents Chemother. 2006 Jun;50(6):2272-3. No abstract available.

33.

In vitro activities of DX-619 and comparison quinolones against gram-positive cocci.

Wickman PA, Black JA, Moland ES, Thomson KS.

Antimicrob Agents Chemother. 2006 Jun;50(6):2255-7.

34.
35.

Failure of cefepime therapy in treatment of Klebsiella pneumoniae bacteremia.

Song W, Moland ES, Hanson ND, Lewis JS, Jorgensen JH, Thomson KS.

J Clin Microbiol. 2005 Sep;43(9):4891-4.

37.
38.

Escherichia coli: development of carbapenem resistance during therapy.

Hong T, Moland ES, Abdalhamid B, Hanson ND, Wang J, Sloan C, Fabian D, Farajallah A, Levine J, Thomson KS.

Clin Infect Dis. 2005 May 15;40(10):e84-6. Epub 2005 Apr 13.

PMID:
15844056
39.

Cefdinir: an oral alternative to parenteral cephems.

Chatterjee A, Moland ES, Thomson KS.

Diagn Microbiol Infect Dis. 2005 Apr;51(4):259-64.

PMID:
15808317
40.

Plasmid-mediated carbapenem-hydrolyzing enzyme KPC-2 in an Enterobacter sp.

Hossain A, Ferraro MJ, Pino RM, Dew RB 3rd, Moland ES, Lockhart TJ, Thomson KS, Goering RV, Hanson ND.

Antimicrob Agents Chemother. 2004 Nov;48(11):4438-40.

41.
42.

Use of beta-lactamase inhibitors in disk tests to detect plasmid-mediated AmpC beta-lactamases.

Black JA, Thomson KS, Pitout JD.

J Clin Microbiol. 2004 May;42(5):2203-6.

43.

A larval Devonian lungfish.

Thomson KS, Sutton M, Thomas B.

Nature. 2003 Dec 18;426(6968):833-4.

PMID:
14685237
44.

NmcA carbapenem-hydrolyzing enzyme in Enterobacter cloacae in North America.

Pottumarthy S, Moland ES, Juretschko S, Swanzy SR, Thomson KS, Fritsche TR.

Emerg Infect Dis. 2003 Aug;9(8):999-1002. Erratum in: Emerg Infect Dis. 2003 Sep;9(9):1188.

45.

Discovery of CTX-M-like extended-spectrum beta-lactamases in Escherichia coli isolates from five US States.

Moland ES, Black JA, Hossain A, Hanson ND, Thomson KS, Pottumarthy S.

Antimicrob Agents Chemother. 2003 Jul;47(7):2382-3. No abstract available.

46.

Plasmid-mediated, carbapenem-hydrolysing beta-lactamase, KPC-2, in Klebsiella pneumoniae isolates.

Smith Moland E, Hanson ND, Herrera VL, Black JA, Lockhart TJ, Hossain A, Johnson JA, Goering RV, Thomson KS.

J Antimicrob Chemother. 2003 Mar;51(3):711-4.

PMID:
12615876
47.

Occurrence of newer beta-lactamases in Klebsiella pneumoniae isolates from 24 U.S. hospitals.

Moland ES, Black JA, Ourada J, Reisbig MD, Hanson ND, Thomson KS.

Antimicrob Agents Chemother. 2002 Dec;46(12):3837-42.

48.

Unusual Salmonella enterica serotype Typhimurium isolate producing CMY-7, SHV-9 and OXA-30 beta-lactamases.

Hanson ND, Moland ES, Hossain A, Neville SA, Gosbell IB, Thomson KS.

J Antimicrob Chemother. 2002 Jun;49(6):1011-4.

PMID:
12039894
49.

BetalasEN: microdilution panel for identifying beta-lactamases present in isolates of Enterobacteriaceae.

Sanders CC, Ehrhardt AF, Moland ES, Thomson KS, Zimmer B, Roe DE.

J Clin Microbiol. 2002 Jan;40(1):123-7.

50.

Supplemental Content

Loading ...
Support Center